M. Avital-Shmilovici, D. Shabat / Bioorg. Med. Chem. 18 (2010) 3643–3647
3647
ative to TMS (d = 0 ppm) and the coupling constants J in Hz. The
4.6. Compound 3
spectra were recorded in CDCl3 as a solvent at room temp unless
stated otherwise. All reagents, including alcohol oxidase, salts
and solvents, were purchased from Sigma–Aldrich.
To a solution of compound 3g (103 mg, 0.15 mmol) in dry THF
(2 mL) and pyridine (153 L, 1.90 mmol) was added methyl-chlo-
roformate (138 L, 1.78 mmol) dropwise with a syringe at 0 °C.
l
l
4.2. Compound 3c
The reaction mixture was stirred for 1 h, while warming to room
temperature and monitored by TLC (EtOAc/Hex 2:3). Upon comple-
tion, the reaction mixture was diluted with EtOAc, and washed
with saturated solution of NH4Cl. The organic layer was separated,
dried over MgSO4, and evaporated under reduced pressure. The
crude product was purified by column chromatography on silica
gel (EtOAc/Hex 2:3) to give compound 3h (92 mg, 77%) as a yellow
oil. The compound was (92 mg, 0.11 mmol) directly dissolved in
Compound 3c was synthesized as previously reported.16
4.3. Compound 3e
Compound 3e was synthesized as previously reported.11
4.4. Compound 3f
dry THF (2 mL) under Argon atmosphere and TBAF (340 lL, 1 M
in THF) was added. The reaction was stirred in room temperature
for 1 h and was monitored by C-18 RP-HPLC (gradient: 30–100%
ACN in water over 20 min). Upon completion of the reaction, the
solvent was removed under reduced pressure and the crude prod-
uct was purified by using preparative RP-HPLC (gradient: 30–100%
ACN in water over 20 min) to give compound 3 (40 mg, 50%) as a
white powder.
Toluene (15 mL) was heated to reflux (110 °C) under Argon
atmosphere and triphosgene (705 mg, 2.37 mmol) was added.
Then, a solution of compound 3c (560 mg, 1.98 mmol) in 5 mL tol-
uene was slowly added dropwise with a syringe. The reaction was
stirred for 30 min at reflux and monitored by 1H NMR (200 MHz,
CDCl3). After the isocyanate derivative (compound 3d) was ob-
served, the solvent was removed under reduced pressure. A solu-
tion of compound 3e (950 mg, 1.52 mmol) in 9 mL dry THF under
1H NMR (400 MHz, CD3CN): d = 8.48 (1H, br s); 7.99 (1H, d,
J = 8.8 Hz); 7.84–7.82 (3H, m); 7.75 (1H, dd, J = 8.8, 2.2 Hz); 7.54
(2H, s); 7.49 (2H, d, J = 8 Hz); 5.24 (4H, s); 5.21 (2H, s); 4.98 (2H,
s); 3.74 (6H, s). 13C NMR (50 MHz, CD3OD): d = 164.3, 155.6,
152.3, 144.1, 142.8, 142.3, 141.8, 133.3, 132.7, 130.4, 129.7,
128.7, 126.8, 125.1, 118.6, 117.2, 77.0, 65.8, 64.2, 53.9. MS (ESI):
m/z calcd for C28H27BN2O15: 642.1; found: 641.0 [MÀH]À.
Argon, followed by the addition of 25 lL DBTL, was added to the
isocyanate residue. The reaction mixture was allowed to warm to
55 °C and was stirred for 1 h. The reaction was monitored by TLC
(EtOAc/Hex 15:85). The solvent was removed under reduced pres-
sure and the crude product was purified by using column chroma-
tography on silica gel (EtOAc/Hex 1:9) to give compound 3f (1.03
gr, 60%) as a yellow oil.
5. Spectroscopic assay conditions
1H NMR (200 MHz, CDCl3): d = 8.01 (1H, d, J = 10.3 Hz); 7.80
(2H, d, J = 8 Hz); 7.65–7.59 (2H, m); 7.38–7.34 (4H, m); 7.20 (1H,
br s); 5.19 (2H, s); 4.86 (2H, s); 4.68 (4H, s); 4.44–4.35 (2H, m);
1.32 (12H, s); 1.14–1.03 (2H, m); 0.87 (18H, s); 0.04 (21H, s). 13C
NMR (100 MHz, CDCl3): d = 179.2, 152.7, 142.9, 141.4, 139.4,
135.1, 134.4, 131.7, 130.7, 129.7, 128.5, 127.1, 125.8, 119.0,
117.7, 115.3, 83.9, 67.1, 65.2, 60.4, 25.5, 24.7, 24.6, 22.6, À1.6,
À3.7. MS (FAB): m/z calcd for C47H73BN2O11Si3: 936.4; found: 959
[M+Na]+.
The signal developed by the DCR amplification technique was
monitored with a spectrophotometer using a 96-well plate reader.
A total volume of 100 lM incubation mixture was used for each
well. The absorbance was measured upon addition of various
amounts of H2O2 [1.00, 0.10 and 0.01 equiv] at 405 nm.
Acknowledgments
D.S. thanks the Israel Science Foundation (ISF) and the Bina-
tional Science Foundation (BSF) for financial support.
4.5. Compound 3g
Compound 3f (300 mg, 0.32 mmol) was dissolved in 3 mL
MeOH. Catalytic amount of p-TsOH was added to the suspension
and the reaction mixture was stirred at room temperature for
20 min, and monitored by TLC (EtOAc/Hex 1:1). After completion,
the solvent was removed under reduced pressure and the crude
product was purified by using column chromatography on silica
gel (EtOAc/Hex 1:1) to give compound 3g (143 mg, 63%) as a white
powder.
References and notes
1. Johnsson, N.; Johnsson, K. Chem. Biol. 2007, 2, 31.
2. Sagi, A.; Weinstain, R.; Karton, N.; Shabat, D. J. Am. Chem. Soc. 2008, 130, 5434.
3. Weinstain, R.; Sagi, A.; Karton, N.; Shabat, D. Chem. Eur. J. 2008, 14, 6857.
4. He, F.; Tang, Y.; Yu, M.; Wang, S.; Li, Y.; Zhu, D. Adv. Funct. Mater. 2006, 16, 91.
5. Zhu, L.; Anslyn, E. V. Angew. Chem., Int. Ed. 2006, 45, 1190.
6. Nam, J. M.; Thaxton, C. S.; Mirkin, C. A. Science 2003, 301, 1884.
7. Niemeyer, C. M.; Adler, M.; Wacker, R. Trends Biotechnol. 2005, 23, 208.
8. Sano, T.; Smith, C. L.; Cantor, C. R. Science 1992, 258, 120.
9. Sella, E.; Shabat, D. Chem. Commun. 2008, 5701.
10. Yoon, H. J.; Mirkin, C. A. J. Am. Chem. Soc. 2008, 130, 11590.
11. Sella, E.; Shabat, D. J. Am. Chem. Soc. 2009, 131, 9934.
12. Amir, R. J.; Pessah, N.; Shamis, M.; Shabat, D. Angew. Chem., Int. Ed. 2003, 42,
4494.
13. Sagi, A.; Segal, E.; Satchi-Fainaro, R.; Shabat, D. Bioorg. Med. Chem. 2007, 15,
3720.
14. Lo, L.-C.; Chu, C.-Y. Chem. Commun. 2003, 2728.
15. Thomas, S. W., 3rd; Joly, G. D.; Swager, T. M. Chem. Rev. 2007, 107, 1339.
16. Avital-Shmilovici, M.; Shabat, D. Bioorg. Med. Chem. Lett. 2009, 19, 3959.
1H NMR (200 MHz, MeOD): d = 7.99 (1H, d, J = 10.3 Hz); 7.76
(2H, d, J = 8 Hz); 7.64–7.59 (2H, m); 7.38–7.34 (4H, m); 5.13 (2H,
s); 4.88 (2H, s); 4.61 (4H, s); 4.41–4.29 (2H, m); 1.29 (12H, s);
1.08–0.99 (2H, m); 0.03 (9H, s). 13C NMR (100 MHz, MeOD):
d = 176.3, 150.7, 144.6, 140.4, 135.8, 135.3, 132.8, 131.5, 128.9,
127.9, 126.6, 119.7, 118.4, 84.7, 65.9, 60.7, 30.4, 25.5, 17.7, -0.9.
MS (FAB): m/z calcd for C35H45BN2O11Si: 708.3; found: 731
[M+Na]+.